Clearside Biomedical, Inc.CLSDNASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank38
Year-over-Year Change
Year-over-year operating cash flow growth rate
Percentile
P38
Within normal range
vs 5Y Ago
-0.9x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | -15.88% |
| Q2 2025 | 18.89% |
| Q1 2025 | -10.96% |
| Q4 2024 | 11.14% |
| Q3 2024 | -4.10% |
| Q2 2024 | 27.65% |
| Q1 2024 | -1686.06% |
| Q4 2023 | 108.15% |
| Q3 2023 | -13.79% |
| Q2 2023 | 26.01% |
| Q1 2023 | -28.70% |
| Q4 2022 | 9.36% |
| Q3 2022 | -13.65% |
| Q2 2022 | -240.61% |
| Q1 2022 | -23.41% |
| Q4 2021 | 254.18% |
| Q3 2021 | 52.83% |
| Q2 2021 | -25.02% |
| Q1 2021 | -25.32% |
| Q4 2020 | -66.70% |
| Q3 2020 | 17.36% |
| Q2 2020 | -14.88% |
| Q1 2020 | -265.96% |
| Q4 2019 | 127.93% |
| Q3 2019 | 39.87% |
| Q2 2019 | 20.52% |
| Q1 2019 | 47.84% |
| Q4 2018 | -23.02% |
| Q3 2018 | -0.77% |
| Q2 2018 | -25.02% |
| Q1 2018 | -3.71% |
| Q4 2017 | -12.12% |
| Q3 2017 | -16.54% |
| Q2 2017 | -5.22% |
| Q1 2017 | -70.04% |
| Q4 2016 | -1.29% |
| Q3 2016 | -16.25% |
| Q2 2016 | -24.73% |
| Q1 2016 | -14.81% |
| Q4 2015 | -21.52% |